Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACCELIO
2023-510506-41-00Phase 2Authorised
- Sponsor
- TheraOp gGmbH
- Start
- Jul 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by TheraOp gGmbH. Primary endpoint: Completion rate. Planned start Jul 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-510506-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510506-41-00.